Study detail
RecruitingPhase 4
Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
Bernstein Clinical Research Center
Summary
use of lanadelumab in patients with acquired angioedema
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Detailed criteria
Inclusion Criteria: * A diagnosis of AAE with recurrent attacks without urticaria (decreased C1INH functional, quantitative levels, decreased C4 and decreased C1q levels, no family history of angioedema), presence of anti-C1INH antibody and/or paraproteinemia (e.g. monoclonal gammopathy of unknown significance) * historical attack rate of \>= on attack per month prior to starting tranexamic acid (TAA) Exclusion Criteria: * History of anaphylaxis or hypersensitivity to biologics * History of major systemic disease not well controlled in opinion of the PI * Women who are pregnant or breast fe…
Interventions
- BiologicalLanadelumab 300 mg
no other intervention
Location
- Bernstein Clinical Research Center, LLCCincinnati, Ohio